Coherus OncologyFRA:8C5 -4.27%45 Gross Margin % is 69.02% as of Mar. 2026, which is 3% above its 10-year median of 67.24. GuruFocus rates FRA:8C5 with a GF Score™ of 45/100 and a GF Value™ of €0.69 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 734 Biotechnology companies, Coherus Oncology ranks better than 57.22% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Coherus Oncology had a gross margin of 69.02% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Coherus Oncology Gross Margin % Related Terms
Coherus Oncology Gross Margin % Historical Data
* Premium members only.
The historical data trend for Coherus Oncology's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:8C5 vs TARA, KPTI, CNTN: Gross Margin % Comparison
For the Biotechnology subindustry, Coherus Oncology's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Coherus Oncology Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Coherus Oncology's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Coherus Oncology's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Coherus Oncology (FRA:8C5) has a Gross Margin % of 69.02% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Coherus Oncology and its competitors. This is near median its historical median of 67.24. Over the past decade, Coherus Oncology's Gross Margin % has ranged from 38.19 to 95.20. According to the industry distribution chart, Coherus Oncology ranks #314 out of 734 companies in the Biotechnology industry, placing it in the top 42.8%.
Is Coherus Oncology's Gross Margin % too high?
Coherus Oncology's current Gross Margin % of 69.02% is near median its 10-year median of 67.24. Over the past 10 years, this metric has ranged from a low of 38.19 to a high of 95.20. The Biotechnology industry median Gross Margin % is 60.80. Coherus Oncology's value of 69.02% is 13.5% above this industry median. Based on the distribution chart, Coherus Oncology ranks #314 out of 734 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Coherus Oncology has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Coherus Oncology's Gross Margin % compare to TARA and KPTI?
According to the Biotechnology industry distribution chart, Coherus Oncology ranks #314 out of 734 companies for Gross Margin %. This puts Coherus Oncology in the upper half of its industry. The industry median Gross Margin % is 60.80. Coherus Oncology's value of 69.02% is 13.5% above this benchmark. Historically, Coherus Oncology's own Gross Margin % has ranged from 38.19 to 95.20 over the past decade. While the company's 10-year median is 67.24 vs. the industry median of 60.80, Coherus Oncology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.80, based on 734 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Coherus Oncology's current Gross Margin % of 69.02% is 13.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Coherus Oncology and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Coherus Oncology's current Gross Margin % is 69.02%, which is near median its own 10-year median of 67.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coherus Oncology stock overvalued right now?
Based on GuruFocus' analysis, Coherus Oncology (FRA:8C5) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.69, compared to a current price of €1.26 — trading 82.2% above its estimated fair value. The current Gross Margin % is 69.02%, which is near median its 10-year median of 67.24 and 13.5% above the Biotechnology industry median of 60.80. Coherus Oncology's overall GF Score™ is 45/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Coherus Oncology (FRA:8C5), the current Gross Margin % is 69.02% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Coherus Oncology (FRA:8C5) Overvalued in 2026?
Based on GuruFocus' analysis, Coherus Oncology stock appears to be overvalued.
The current stock price of €1.26 is trading 82.2% above its estimated GF Value™ of €0.69.
GuruFocus considers Coherus Oncology to be Significantly Overvalued.
Key valuation signals for FRA:8C5:
Gross Margin %: 69.02% (near median its 10-year median of 67.24)
GF Value™: €0.69 vs. price of €1.26 (82.2% above fair value)
Industry Position: 13.5% above the Biotechnology median (#314 of 734)
No single metric tells the full story. See the FRA:8C5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.
45GF Score
Get the complete analysis for FRA:8C5
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:8C5 has been successfully added to your 
